1995 Outstanding Contributions in Education
Peter I. Jatlow will receive the 25th annual award, sponsored by SmithKline Beecham Clinical Laboratories.
Jatlow graduated from Union College, and received his M.D. from SUNY Downstate Medical Center. Following an internship at Montefiore Hospital, NY, and residency at Yale–New Haven Hospital, which included training in clinical chemistry under the tutelage of David Seligson, Jatlow spent 2 years in Alaska as chief of pathology at the Alaska Native Medical Center of the US Public Health Service. He then returned to Yale, where he is currently professor and chairman of the Department of Laboratory Medicine at the Yale University School of Medicine and chief of Laboratory Medicine at the Yale–New Haven Hospital. He also holds a joint appointment as professor of psychiatry.
Jatlow’s educational responsibilities at Yale have included the roles of director of undergraduate medical studies and program director of residency training in the Department of Laboratory Medicine. The problem-solving and hypothesis-testing abilities obtained through exposure to research are, in Jatlow’s opinion, an important component of the educational process and critical to the creative practice of clinical chemistry as well as the other disciplines of laboratory medicine. Jatlow also believes that data are best interpreted by those who understand how the data are derived. He believes that clinical laboratory scientists can provide a special and unique perspective to interpretation of clinical laboratory data if they are able to integrate knowledge of the data’s clinical significance and scientific basis with an understanding of the constraints and capabilities of the biotechnology through which it is produced.
Jatlow has been the recipient of the AACC’s Award for Contributions in a Selected Area of Research, the Connecticut Valley section’s Seligson–Golden Award, the Irving Sunshine Award in Clinical Toxicology of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology, and the Gerald T. Evans and Cotlove Awards of the Academy of Clinical Laboratory Physicians and Scientists.
Jatlow was a member of the Biochemistry Research Review Committee of the National Institute on Drug Abuse for 4 years. He has also served on the National Board of Medical Examiners FLEX Program Test Material Development Committee, and the American Board of Pathology’s Chemical Pathology Test Committee. Activities in AACC have included membership on the Council and Nominating Committee and past presidency of the Connecticut Valley Section.
Jatlow has previously served on the editorial boards of Clinical Chemistry, Clinica Chimica Acta, Standard Methods in Clinical Chemistry, and Journal of Analytical Toxicology, and is currently on the editorial boards of the American Journal of Clinical Pathology and Therapeutic Drug Monitoring.
Jatlow’s research interest in the toxicology and clinical pharmacology of psychotropic drugs and drugs of abuse began in 1969 with the initiation at Yale of one of the first methadone treatment programs, which required establishment of a drug abuse screening program. His research has been particularly concerned with the toxicology and pharmacology of cocaine, and he published some of the earliest studies of the clinical pharmacology and pharmacokinetics of cocaine. Currently, his research has focused on the biochemical and neuropharmacology of combined cocaine and ethanol abuse. Recently, as director of an AIDS Clinical Trials Group core pharmacology laboratory, he has also been studying the interaction between drugs of abuse and drugs used to manage AIDS.
1985 Outstanding Contributions in a Selected Area of Research
Peter I. Jatlow will receive the 13th AACC Award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research. This award is sponsored by Roche Diagnostic Systems.
Dr. Jatlow was born in New Brunswick, New Jersey. He received his B.S. from Union College in 1957 and his M.D. in 1961 from the State University of New York, Downstate Medical Center. After a mixed medicine-surgery internship at Montefiore Hospital in New York, Dr. Jatlow spent the next four years as a resident and postdoctoral trainee in pathology and laboratory medicine at Yale-New Haven Hospital and the Yale University School of Medicine. He received his training in clinical chemistry under the guidance of David Seligson. From 1966 to 1968, Dr. Jatlow was in the U.S. Public Health Service, serving as chief of pathology at the Alaskan Native Medical Center in Anchorage, Alaska. In July 1968 he returned to Yale, where he has been on the faculty ever since. He currently is professor and chairman of the Department of Laboratory Medicine there and chief of clinical laboratories at Yale-New Haven Hospital. He also holds a joint appointment as professor in the Department of Psychiatry.
Dr. Jatlow has served on the Editorial Boards of Clinical Chemistry and the Journal of Analytical Toxicology. He is currently a member of the editorial boards of Therapeutic Drug Monitoring, and Clinica Chimica Acta. During the 1983–1984 academic year he served as president of the Academy of Clinical Laboratory Physicians and Scientists. He has served on numerous national committees. He is currently a member of the Chemical Pathology Test Committee of the American Board of Pathology. He also serves as a member of the Drug Abuse Biomedical Research Review Committee (Study Section) of the National Institute on Drug Abuse.
Dr. Jatlow’s research interests have been in the areas of analytical and clinical toxicology and clinical pharmacology. His early interests were concerned with the clinical correlation of drug concentrations in serum after overdose. More recently, his research has focused on the measurement and clinical pharmacology of psychotropic and psychotherapeutic drugs, including cocaine and the tricyclic antidepressants. His laboratory was among the first to evaluate cocaine concentrations in plasma after various routes of administration and their relationship to behavioral changes. Dr. Jatlow is the author of more than 100 publications, most of them in the fields of clinical and analytical toxicology and clinical psychopharmacology.